Author Archives: admin

Facial Injectable Market Growth Analysis, Size Projection, Key Insights, COVID-19 Impact Analysis and Future Trends By 2025 – Cole of Duty

By adminJuly 10, 2020Stem Cell Clinic

Global Facial Injectable Market Share, Growth and Trends Analysis by Type (Botulinum Toxin, Hyaluronic Acid, Polymers and Particles and Collagen), Application (Facial Line Correction Treatment, Face Lift and Lip Treatments), End User (Hospitals, Specialty Clinics and Spa & Beauty Clinic) and Region (North America, Europe, Asia-Pacific and Middle East & Africa) Forecast till 2025

Anti-ageing, face rejuvenation and cosmetic treatments have changed the rules of engagement and reinvention. Today, its possible to change the basic elements of yourself to fulfil the basic desire of humans to be young.

Thefacial injectable marketis been driven by numerous factors. However rising proportion and absolute numbers of older people led by baby boomers generation with good incomes are the critical driving factor for the global facial injectable market. According to the World Health Organization estimates between 2015 and 2050, the proportion of the worlds population over 60 years will double from 12% to 22% which will be a positive development for the market.

Another critical driver and the motive behind the market is the primal desire to remain young. The extension of life has been a primal desire of humanity and a mainstay motif in the history of scientific pursuits and ideas throughout history, from the Egyptian Smith medical papyrus, Ayurveda practitioners, alchemists, etc. This primal desire for youth has driven the market for anti-ageing drugs since time immemorial.

Request Free Sample Copy at:https://www.marketresearchfuture.com/sample_request/1527

The growing influence of lifestyle, fashion and film industry have led to rising demand of medications to slow the ageing and its signs. Health and youth wellness have become a status symbol and youthful appearance is penetrating peoples life and there is increasing consumerization of youth. The growth of media such as television and lifestyle magazines have led to a craze for youthful appearance.

Other driving factors are primal desire of humans to remain young, influence of lifestyle industry and rising awareness about wellbeing, high levels of disposable incomes etc. The market restraints are skepticism and concerns of safety regarding the unrestricted use of anti-ageing drugs without greater and clearer experimental validation. Ambiguity of the definition of anti-ageing drugs is also a cause of concern. For example, numerous cosmetics have been included or claimed to have anti-aging effects and have been termed as Cosmeceuticals. Cosmeceutical is defined by the cosmetic industry as cosmetic products that have medicinal or drug like effects which is not supported by the U.S. Food and Drug Administration (FDA) or the Food, Drug and Cosmetic Act.

The facial injectable market is a technological oriented market having a high research and development potential due to advancement in technologies and cellular understanding which are keys to unravel the exact mechanism of ageing. Gene therapy, stem cell technology and targeted delivery of nutrients using biotechnology are expected to open the gates for anti-ageing drugs. The development of biomarkers for physiochemical modifications in the body such as alteration of concentration of an enzyme or hormone provides another exiting avenue for the future market. For example, levels of homocysteine has been proposed as a marker of age related changes in the body so as to compensate the change by drugs.

From a market perspective the facial injectable market is ripe with mergers, acquisitions and partnerships. For example, in 2017, cosmetic giant LOral acquired skincare brands such as CeraVe, AcneFree and Ambi from Valeant Pharmaceuticals at ~ $1.25 billion. In 2016, Johnson & Johnson acquired Vogue International LLC, for greater than $3 billion to strengthen its consumer segment. Thus, partnerships seem to be a good strategy to curtail the developmental cost of any new facial injectable drug. Acquisition of other companies also leads to expansion of product lines which improves market penetration and exposure.

The global market for facial injectable is expected to reach USD 9.04 billion by the end of the forecasted period 2023 and is expected to grow at a CAGR of 13.2%

Global facial injectable market is segment by types and applications. Based on types the market is sub-segmented as botulinum toxin, hyaluronic acid, polymers & particles, and collagen. On the basis of application, the market is sub-segmented into facial line correction treatment, face-lift, lip treatments and others.

The key players in his market are Allergan, Galderma, Integra Lifesciences, Merz Pharma, Sanofi, SciVision Biotech Inc, Sinclair. Suneva Medical and Valeant Pharmaceuticals.

Regional outlook for the facial injectable market

The facial injectable market is dominated by North America. The U.S. is the prime mover of the facial injectable market. However, it has to be noted that Latin America despite its lower per capita income has a disproportionate share of the market. It is estimated that Latin America will be the fastest in the future. As of the present the European regions is expected to be the second largest market globally, with countries like Germany, UK and France playing a prominent role in the market. Germany accounts for both the largest and the fastest growing nation in the European region facial injectable market, followed by France.

Asia Pacific market is expected to be the fastest future growing market during the forecast period 2016-2023. The Asia Pacific region will be led by countries such as China and India. However the greatest hindering reasons for the Asia pacific region market is the poor per capita income and the high cost of treatment. Nations such as Thailand etc. have a disproportionate share of Asia Pacific market considering their low income as compared to the U.S. The market of these nations is influenced to a considerable degree by the tourism and fashion industry. Advertisement and greater exposure seems to be the best strategy to be a market leader along with product development. The return on investment for advertisement and publicity is very high for the cosmetic surgery market.

There has been a definite shift of the cosmetic surgery market from the developed regions to the developing ones particularly Latin America and Asia Pacific countries such as Thailand. The market represents a clustered outlook with urban metropolitan cities especially with adjoining tourism and fashion industry having an extreme lead over the rural areas. Large tourism clusters such as Miami, Bangkok, Bali etc. have a disproportionate share of the market due to the large volume of cosmetic surgeries.

The porn industry also is affecting the market and it has been seen that the rise of cosmetic surgeries has a linear relationship with the quality and bandwidth of the internet. Thus cities such as Los Angeles, Las Vegas etc. are the leading clusters of cosmetic surgery market.

Browse Complete Research Report with COVID-19 Impact Analysis at:https://www.marketresearchfuture.com/reports/facial-injectable-market-1527

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [emailprotected]

More here:
Facial Injectable Market Growth Analysis, Size Projection, Key Insights, COVID-19 Impact Analysis and Future Trends By 2025 - Cole of Duty

R3 International Now Offering Stem Cell Therapy Program for Crohns Disease, IBD and Ulcerative Colitis – PR Web

By adminJuly 10, 2020Stem Cell Doctors

Stem Cell Therapy for Crohns Disease and IBD in Mexico (888) 988-0515

SAN DIEGO (PRWEB) July 08, 2020

R3 International is now offering effective stem cell therapy for Crohns disease, Ulcerative Colitis and IBD with a new program in Mexico. The new program provides up to 200 million stem cells for patients, with treatment starting at only $2975.

Millions of individuals worldwide suffer from chronic abdominal issues that affect every aspect of daily life and lead to difficulty with functioning. Traditional treatments are often insufficient and entail significant side effects.

According to R3 CEO David Greene, MD, MBA, "Stem cell therapy for Crohns, UC and IBD is not only safe and effective, but you don't have the bad side effects like you do with traditional drugs. We've been very successful in Mexico because the therapies are not only clinically and cost effective, but we offer very high numbers of stem cells for pricing exponentially less than the US, Panama or others!"

Studies on stem cell therapy for inflammatory diseases such as Crohns are showing that they are highly effective at regulating one's immune response (Nat Rev Nephrol 2018). This typically helps reduce flare ups and pain in patients, helping to increase quality of life tremendously.

Since R3 Stem Cell International opened in Tijuana, outcomes for these inflammatory conditions have been tremendous, with patients receiving anywhere from 30 million to 200 million stem cells.

The cells offered at R3 International come from a lab with a perfect safety record and quality assurance standards that exceed those of the FDA. No preservative is necessary, so the cell viability for the biologic exceeds 95% typically.

According to CEO Dr. Greene, "We made sure to partner with a lab that has a perfect safety record and only cultures cells between three and five generations. This means counts are high, and so is the potency of the cells!"

The treatment process starts with a free phone consultation with one of R3's licensed, experienced stem cell doctors. Once the treatment recommendation is made and the procedure is scheduled, the patient's designated concierge representative will assist with travel logistics. Transportation is included to and from the clinic from San Diego International Airport, which is only 20 minutes away.

Treatment starts at $2975 for 30 million live stem cells, and goes up $1000 for a total of 50 million. If a patient desires, a five day stay will include three treatments totaling 150 to 200 million stem cells. Or there is an option for four visits over a year as well, both starting at $8975 all inclusive.

To start the seamless process of obtaining treatment, visit for more information and call (888) 988-0515 to schedule the phone consultation.

Share article on social media or email:

Originally posted here:
R3 International Now Offering Stem Cell Therapy Program for Crohns Disease, IBD and Ulcerative Colitis - PR Web

Eucalyptus necklace and other unproven Covid-19 cures raise alarm in Indonesia – The Star Online

By adminJuly 10, 2020Stem Cell Doctors

JAKARTA (The Jakarta Post/ANN): A minister touted a necklace made of eucalyptus, while researchers, including from the national intelligence agency, announced the discovery of a combination of drugs and cutting-edge stem cell therapies.

These were among a litany of claims of Covid-19 cures in Indonesia that have alarmed doctors and the consumer protection foundation.

The Indonesian Consumers Foundation (YLKI), in a letter earlier this month to State Secretary Pratikno, expressed concerns over plans to produce anti-coronavirus medicines that had not passed clinical trials. The State Secretary is a key aide to President Joko Widodo and is involved in the day-to-day running of the government.

In Indonesia, the Food and Drug Monitoring Agency (BPOM), the equivalent of the United States Food and Drug Administration, conducts extensive clinical trials to ensure the safety and efficacy of any proposed new drug.

Last month, researchers at Airlangga University in East Java province and the State Intelligence Agency (BIN) announced the discovery of five combinations of drugs to fight Covid-19, as well as two types of stem cell therapies that reportedly inhibit the coronavirus that causes Covid-19.

The announcement was criticised by doctors, who were also perplexed by the involvement of an intelligence agency in a medical endeavour.

Responding to the joint announcement by BIN and the university, Dr Pandu Riono, who teaches at the University of Indonesia's medical school, issued a reminder that public safety should remain paramount even during an emergency situation such as a pandemic.

He also appealed to government agencies to operate within their respective spheres and never to ignore science.

YLKI chairman Tulus Abadi noted that many of the claims of Covid-19 cures increasingly being circulated were, in fact,"unlicensed and whose effectiveness has not been scientifically proven".

"BPOM must increase monitoring and warn the parties making such claims that they are not based on required clinical trials. Even if the claim was made by a minister," he said.

Last week, Agriculture Minister Syahrul Yasin Limpo announced that his ministry would begin mass producing an anti-Covid-19 necklace made of eucalyptus in August. He claimed that it could kill 80 per cent of the virus in a patient in just half an hour.

A few days later, the ministry's research and development head, Fadjry Djufry, backtracked, saying that the products - which included hand-held inhalers and roll-ons - were merely for aromatherapy.

He said they would not be labelled as anti-viral, although they could treat known Covid-19 symptoms such as shortness of breath.

In a recent webinar involving medical doctors, Dr Lucia Rizka Andalusia, the drug registration director at BPOM, said the agency would not close the door to creativity in efforts to find and use effective herbal traditional medicines against Covid-19, but emphasised that it must ensure safety.

But the chairman of the independent Indonesian Doctors Council, Dr Sukman Tulus, issued a warning to his colleagues.

Administering drugs, herbal medicines and traditional healing substances that are "not yet licensed and do not have clear standards would amount to a breach of professional duty and even a breach of law" for medical doctors, he said. - The Jakarta Post/Asia News Network

See more here:
Eucalyptus necklace and other unproven Covid-19 cures raise alarm in Indonesia - The Star Online

Orchard Therapeutics, MolMed Extend Gene Therapy Mfg. Pact – Contract Pharma

By adminJuly 10, 2020Stem Cell Treatment

MolMed to support the development and manufacture of vectors and drug products for Orchards investigational hematopoietic stem cell (HSC) gene therapies.

Contract Pharma Staff07.09.20

Orchard Therapeutics and MolMed S.p.A have extended their collaboration initiated in April 2018, through June 2025. MolMed will continue to support activities related to the development and manufacture of vectors and drug products for several of Orchards investigational ex vivo hematopoietic stem cell (HSC) gene therapies, including OTL-200 for metachromatic leukodystrophy (MLD), OTL-103 for Wiskott Aldrich syndrome (WAS), and OTL-203 for mucopolysaccharidosis type I (MPS-I).

MolMed is the first company to have obtained good manufacturing practice (GMP) authorization for the gene and cell therapy markets in Europe and is the manufacturer for Strimvelis, Orchards ex vivo HSC gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) and the first such treatment approved by the European Medicines Agency (EMA).

OTL-200 for MLD is currently under review by the EMA with a decision expected later this year.

See original here:
Orchard Therapeutics, MolMed Extend Gene Therapy Mfg. Pact - Contract Pharma

Oncologie Expands and Strengthens Management Team with Key Appointments and Promotions – GlobeNewswire

By adminJuly 10, 2020Stem Cell Medicine

July 09, 2020 07:00 ET | Source: Oncologie, Inc.

-Appoints Matthew Osborne as Chief Financial Officer-

-Names Hagop Youssoufian, M.D., as Interim Chief Medical Officer-

-Hires Bill McDonald, Ph.D., as Vice President of CMC-

-Promotes Kerry Culm-Merdek, Ph.D., to Vice President of Clinical Development-

WALTHAM, Mass., July 09, 2020 (GLOBE NEWSWIRE) -- Oncologie, Inc., a precision medicine company using an innovative RNA-based biomarker platform to develop novel, targeted oncology therapies, today announced an expansion of its management team with the appointments of Matthew Osborne as Chief Financial Officer, Hagop Youssoufian, M.D., as Interim Chief Medical Officer, Bill McDonald, Ph.D., as Vice President of Chemistry, Manufacturing and Controls (CMC), as well as the promotion of Kerry Culm-Merdek, Ph.D., to Vice President of Clinical Development.

We are pleased to expand Oncologies management team with the additions of Matt, Hagop and Bill, and the promotion of Kerry, and look forward to their contributions, said Laura Benjamin, Ph.D., Founder and CEO of Oncologie. Their collective experience and leadership will be critical as we further develop and deploy our RNA-based biomarker platform to advance the state of the art of precision medicine to identify the right patients for our clinical stage programs, Navicixizumab and Bavituximab.

Mr. Osborne brings to Oncologie more than 20 years of leadership, financial and industry experience, gleaned from years on Wall Street and through professional roles with small to large cap biotechnology companies. In these roles, he successfully led multiple equity financings, applying his expertise across disciplines spanning scientific, financial, strategic planning, investor relations and corporate communications functions. Before joining the company in 2020, Mr. Osborne served as Chief Financial Officer at Unum Therapeutics, Inc. Prior to joining Unum Therapeutics, Mr. Osborne served as Head of Corporate Affairs, Communications and Investor Relations at Voyager Therapeutics, Inc., and through similar roles at Shire, Plc (acquired by Takeda Pharmaceutical Company in 2019), Synageva BioPharma Corp. (acquired by Alexion Pharmaceuticals, Inc. in 2015) and Vertex Pharmaceuticals Incorporated. Mr. Osbornes Wall Street experience includes serving as a sell-side analyst at Lazard Capital Markets and Leerink Swann (now SVB Leerink), where he covered small to large cap biotechnology companies, analyzed drug launches and launched several initial public offerings. He received a B.S. in Biology from Syracuse University and an M.B.A. from the DAmore-McKim School of Business at Northeastern University.

Dr. Youssoufian is a physician-scientist with more than 25 years of experience in drug development working with seed-stage ventures to multi-national biotech and pharmaceutical corporations. After a successful academic career as a clinician, teacher and NIH-funded investigator, he held increasingly senior roles in clinical and translational science including Head of Experimental Medicine at Bristol-Myers Squibb Company, Distinguished Scientist at Sanofi Aventis, Chief Medical Officer at ImClone Systems Incorporated, President of Research and Development and Chief Medical Officer at Ziopharm Oncology, Inc., Executive Vice President of Research and Development at Progenics Pharmaceuticals, Inc., and Chief Medical Officer at BIND Therapeutics, Inc. He supported or led the development and approval of a number of medicines including Sprycel, Taxotere, Erbitux, Cyramza, Lartruvo and Copiktra. He is an elected member of the American Society for Clinical Investigation, the recipient of many national and international awards, and the author of more than 100 publications. He received a B.S. in biology from Boston College and M.Sc./M.D. from University of Massachusetts Medical School, followed by fellowships at Johns Hopkins University, Harvard University and the Massachusetts Institute of Technology.

William Bill McDonald, Ph.D., brings more than 20 years of experience in process development and the manufacturing of antibodies, recombinant enzymes, antigens, antibody targets, viral vectors and vaccines. Prior to joining Oncologie, Bill served as Vice President, CMC at Contrafect Corporation where he was responsible for all CMC activities for Contrafects novel biologics platform of anti-microbial therapies. Previously, Bill served as Executive Director and Manufacturing Site Head at Celldex Therapeutics, Inc., where he oversaw the Fall River GMP manufacturing facility and was responsible for internal manufacturing of all early clinical stage biologics. Bill also held roles of increasing responsibility at Synageva BioPharma Corp. (acquired by Alexion Pharmaceuticals, Inc. in 2015), including Senior Director of Process Development. He also previously served as Head of Process Science at Pfizer, Inc., Director of Antigen Production at Genocea Biosciences Inc. and Director of Biochemistry at VaxInnate Corporation. Within the scope of technical operations, he has supported the development and manufacture of several approved biologics including Kanuma, Soliris and Strensiq. Bill received a B.S. in Microbiology from the University of Florida and received a Ph.D. in Molecular Biology at Cornell University.

Kerry Culm-Merdek, Ph.D., brings over 15 years of clinical drug development expertise and experience in small molecule and therapeutic protein development in rare disease and oncology indications including her role as Head of Clinical Pharmacology and Quantitative Bioanalytics at ImmunoGen Inc., where she was responsible for clinical pharmacology strategy for global clinical and preclinical development of oncology therapies. Prior to joining ImmunoGen, Kerry spent 13 years at Sanofi Genzyme, most recently serving as a Global Project Head, where she led the therapy project teams for Fabry disease, Gaucher disease type 3 and multiple gangliosidosis/galatosialidosis indications. Kerry received a B.S. in Biochemical Pharmacology from the State University of New York at Buffalo. She received a Ph.D. in Pharmacology and Experimental Therapeutics at Tufts University School of Medicine.

About Bavituximab

Bavituximab is an investigational chimeric monoclonal antibody that targets the activity of phosphatidylserine (PS). Bavituximab is believed to reverse PS-mediated immunosuppression by blocking the engagement of PS with its receptors, as well as by sending an alternate immune activating signal. PS-targeting antibodies have been shown to shift the functions of immune cells in tumors, resulting in multiple signs of immune activation and anti-tumor immune responses. This mechanism may play an important role in allowing other cancer therapies to more effectively attack tumors by reversing the immunosuppression that limits the impact of those treatments. Oncologie is conducting a Phase 2 trial of bavituximab plus pembrolizumab as a second-line treatment in patients with advanced gastric or gastroesophageal cancer. Using its biomarker platform, Oncologie is analyzing patient tissue samples from this on-going trial with results expected later this year to inform future clinical development for this program.

About Navicixizumab

Navicixizumab is an anti-DLL4/VEGF bispecific antibody designed to inhibit both Delta-like ligand 4 (DLL4) in the Notch cancer stem cell pathway as well as vascular endothelial growth factor (VEGF) and thereby induce potent anti-tumor responses while mitigating certain angiogenic-related toxicities. In preclinical studies, navicixizumab demonstrated robust in vivo anti-tumor activity across a range of solid tumor xenografts, including colon, ovarian, lung and pancreatic cancers, among others. In a Phase 1a trial of 66 patients with various types of refractory solid tumors, treatment with single agent navicixizumab generated an overall response in three of 12 (25%) patients with ovarian cancer. In a Phase 1b trial in platinum-resistant ovarian cancer patients who had failed more than two prior therapies including bevacizumab, treatment with navicixizumab plus paclitaxel generated an interim overall response in 10 of 30 (33%) patients. Treatment-related adverse events in the Phase 1b trial were manageable and included hypertension (58%), headache (29%), fatigue (26%) and pulmonary hypertension (18%). Using its RNA-based biomarker platform, Oncologie is analyzing patient tissue samples from all navicixizumab trials with results expected later this year to inform future clinical development with this program. The FDA granted Fast Track designation to navicixizumab for the treatment of high-grade ovarian, primary peritoneal or fallopian tube cancer in patients who have received at least three prior therapies and/or prior treatment with bevacizumab.

About Oncologies RNA-based Biomarker Platform

Predictive biomarkers historically worked on single-driver mutations yet only approximately 10% of cancer patients have known driver mutations with available targeted therapies. Using its proprietary biomarker platform, Oncologie is advancing a new paradigm of precision oncology with an RNA-based approach to identify the dominant biology in the tumor microenvironment. This could improve clinical outcomes by matching patients to therapies with a mechanism of action that targets that specific biology and expand precision medicine to those therapies whose potential remains unrealized. Oncologie is further optimizing the biomarker platforms tumor microenvironment panel through multiple research collaborations, including a collaboration with Moffitt Cancer Center.

About Oncologie, Inc.

Oncologie, Inc. aims to advance the state of the art of precision medicine to dramatically improve the lives of people with cancer. Leveraging a deep understanding of the evolving biology of cancer, Oncologie is developing unique RNA-based biomarker panels to match patients to novel, targeted therapies that modulate the bodys tumor immune system and angiogenesis pathways. Oncologie, Inc., based in Waltham, Massachusetts, and Oncologie Shanghai Co., Ltd., based in Shanghai, China, are subsidiaries of Oncologie, Ltd., and are working with global partners to acquire and further develop innovative drugs for cancer patients around the world. For more information on Oncologie, Inc., please visit https://oncologie.com/.

Investor and Media Contact:

Ashley R. Robinson LifeSci Partners, LLC arr@lifesciadvisors.com

Read this article:
Oncologie Expands and Strengthens Management Team with Key Appointments and Promotions - GlobeNewswire

Global Nicotine Addiction Treatment Market 2020 Business Outlook with Pandemic Scenario Analysis and Forecast 2026|Sosei Group Corporation, CV…

By adminJuly 10, 2020Gene Therapy Clinics

The global Nicotine Addiction Treatment Market and its growth prospects are influenced by a variety of factors. Through our report, we seek to inform the reader regarding the nature of the market, the factors that influence its growth as well as the key players involved. The reader is informed about the market variables in order to provide an understanding of the scope for business activities during the forecast period. The report begins with an evaluation of the current market status. The global Nicotine Addiction Treatment market has a current market valuation of Nicotine Addiction Treatment, and is projected to reach a market value of Nicotine Addiction Treatment by the end of the forecast period 2020 -2026. Our report estimates the CAGR growth that will take place by the end of the forecast period.

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

To register for digital conference click here @ https://www.databridgemarketresearch.com/digital-conference/cell-and-gene-therapy

Market Drivers

High prevalence of tobacco products consumptions acts as a market driver

Vulnerable adult population as adults are at high risk for nicotine addiction also drives the market growth

Increase in government initiatives and polices can also act as a market driver

Rapid adoption of newer formulations and novel dosage forms can boost the market growth

Market Restraints

Limited success of existing smoking cessation methods is also hampering the market growth

Preference of non-pharmacology therapies over pharmacology therapies can hinder the market growth

Patent expiry of major drugs and introduction of generic drugs of branded version is expected to restrict the growth of this market

To know more about the[emailprotected]https://www.databridgemarketresearch.com/reports/global-nicotine-addiction-treatment-market

Segmentation:Global Nicotine Addiction Treatment Market

By Type

(Combustible Tobacco and Smokeless Tobacco),

Treatment Type

(Nicotine Replacement Therapy and Psychological Therapy),

Drugs

(Approved-Drugs, Off-label Drugs and Others),

Product Type (Patch, Gum, Pills, Lozenge, Spray and Others),

Route of Administration

(Oral, Inhalation and Injectable),

Drug Delivery System

(Transdermal Drug Delivery System, Buccal Drug Delivery System and Others),

End-Users

(Hospitals, Homecare, Specialty Clinics, Others),

Geography

(North America, South America, Europe, Asia-Pacific, Middle East and Africa)

Inquiry For Customize Report With Discount at :https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-nicotine-addiction-treatment-market

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact: Data Bridge Market Research Tel: +1-888-387-2818 Email:[emailprotected]

Go here to see the original:
Global Nicotine Addiction Treatment Market 2020 Business Outlook with Pandemic Scenario Analysis and Forecast 2026|Sosei Group Corporation, CV...

Global Precision Cancer Therapies Market Briefing 2020, Trends, Applications, Types, Research, Forecast To 2025 – Red & Black Student Newspaper

By adminJuly 10, 2020Gene Therapy Clinics

Global Precision Cancer Therapies Market 2020 by Company, Regions, Type and Application, Forecast to 2025 offers a detailed sketch of each segment with sub-segment of the global market. The report depicts information regarding the drivers, restraints, opportunities, and trends affecting the global Precision Cancer Therapies market growth. The report provides a point-wise outline of market share, market size, industry partakers, and regional landscape along with statistics, diagrams, & charts showing various noteworthy parameters of the industry landscape. The report studies the market growth analysis with a historical & futuristic perspective for the following parameters; cost, revenue, demands, and supply data (as applicable).

Important data is exemplified in the form of pie outlines, tables, analytical figures, and reference diagrams. The document contains a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. Significant data about market segmentation on the basis of type, application, and regional landscape has been given. Report authors have investigated the principals, players in the global Precision Cancer Therapies market, geological regions, product type, and market end-client applications.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketandresearch.biz/sample-request/146404

NOTE: This report takes into account the current and future impacts of COVID-19 on this industry and offers you an in-dept analysis of Precision Cancer Therapies market.

The key players examination covers various aspects such as company profile, product portfolio, sales analysis, revenue generation through the forecast period from 2020 to 2025. This information will help the reader identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and production by manufacturers during the forecast period of 2015 to 2025. Next, the main region and share information about the global Precision Cancer Therapies market size and value in a particular region have been covered in the report.

Geographically, the report includes the research on production, consumption, revenue, market share and growth rate, and forecast (2015-2020) of the following regions: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina, Colombia, Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

In market segmentation by types, the report covers- Hormone Therapy, Immunotherapies, Targeted Therapy, Monoclonal Antibody Therapy, Gene Therapy

In market segmentation by applications, the report covers the following uses- , Hospitals, Diagnostic Centers, Oncology Clinics, Research Institutes

In market segmentation by manufacturers, the report covers the following companies: Abbott Laboratories, Aveo Pharmaceuticals, OncoGenex Pharmaceuticals, Bayer HealthCare, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Hospira

ACCESS FULL REPORT: https://www.marketandresearch.biz/report/146404/global-precision-cancer-therapies-market-2020-by-company-regions-type-and-application-forecast-to-2025

This Study Will Address Following questions:

Customization of the Report: This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact Us Mark Stone Head of Business Development Phone: +1-201-465-4211 Email: sales@marketandresearch.biz Web: http://www.marketandresearch.biz

See the article here:
Global Precision Cancer Therapies Market Briefing 2020, Trends, Applications, Types, Research, Forecast To 2025 - Red & Black Student Newspaper

13 promising Covid-19 treatments emerging from Israel – The Yucatan Times

By adminJuly 10, 2020Adult Stem Cells

In parallel to vaccine research, theres an urgent need for effective treatments for the respiratory disease caused by the SARS-CoV-2 coronavirus.

ISRAEL (Scientists across the globe are working on vaccines to prevent Covid-19 infection. After initial vaccines are approved, there is an urgent need for effective treatments for the respiratory disease caused by the SARS-CoV-2 coronavirus.

Most potential treatments target the life-threatening lung inflammation typical of covid-19 severe cases. Its caused by a phenomenon called a cytokine storm.

Cytokines are proteins that trigger inflammation as a natural response to infection. In response to a virus overload, in this case, in the lungs, the immune system activates a storm of cytokines. Too many cytokines lead to too much inflammation, which can damage the lungs and cause respiratory distress.

Israeli hospitals were among the first anywhere to use dexamethasone, a steroid drug, to stop cytokines storms and reduce lung inflammation in severely ill Covid-19 patients. However, steroids can suppress the immune response too actively.

Additionally, an Israeli hospital is among the first to do a randomized, double-blind, placebo-controlled clinical trial of ivermectin, a drug to treat parasitic infections in people and animals, to see if it can shorten the duration of the disease if given to Covid-19 patients immediately after diagnosis.

Israelis are also formulating novel therapeutics of their own. Here are 13 potential Israeli treatments using a variety of approaches.

Pluristem On June 11, Pluristem Therapeutics of Haifa announced a multicenter Phase 2 US Food and Drug Administration (FDA) efficacy and safety study of its PLX-PAD cells for treating severe Covid-19 complicated by acute respiratory distress syndrome (ARDS).

PLX, an injected regenerative placenta-derived cell therapy, stimulates the immune systems natural regulatory T cells and M2 macrophages, possibly preventing or reversing a cytokine storm. PLX cells potentially reduce the incidence or severity of Covid-19 pneumonia and pneumonitis.

Pluristem has treated Covid-19 patients under compassionate use programs in the United States and Israel. Initial data from 18 patients showed that 75% were off mechanical ventilation within 28 days.

PLX cells are available off-the-shelf and once commercialized, can be manufactured in large-scale quantities, offering a key advantage in addressing a global pandemic, the company said.

Silkim Jerusalem-based Silkim Pharma recently submitted Coronzot, its novel treatment for Covid-19 patients with moderate to severe symptoms, to the FDAs Investigational New Drug (IND) program.

IND designation would give Silkim permission to start human clinical trials and ship Coronzot across state lines before a marketing application has been approved.

Coronzots novel mechanism targets a pivotal factor in cytokine storms. It removes an inflammatory overaccumulation of labile iron and replaces it with a minute amount of gallium or zinc.

This not only suppresses the storm but also inhibits viral proteins that attack the lungs and heart. Gallium inhibits virus replication and promotes apoptosis (self-destruction) of already invaded cells. Zinc helps suppress inflammatory reactions and enzymes that enable coronavirus replication.

The company is actively engaged in the FDA process. We look forward to finalizing the IND and then moving towards conducting clinical studies of Coronzot for Covid-19, said Silkim Pharma CEO Dror Chevion.

RedHill Biopharma RedHill Biopharma, based in Raleigh, North Carolina, and Tel Aviv, is racing to advance our development program with opaganib for Covid-19, according to a June 10 statement by Dr. Mark L. Levitt, RedHill medical director.

RedHill acquired opaganib from US-based Apogee Biotechnology, which developed this oral drug to fight cancer, inflammation, and viruses.

RedHill has seen encouraging preliminary findings from six Israeli Covid-19 patients given opaganib under compassionate use to reduce lung inflammation. All were weaned from supplemental oxygen and discharged from the hospital without having to receive mechanical ventilation.

RedHill plans a multicenter, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 clinical study on 270 US patients with severe Covid-19 pneumonia.

We are expanding the development program to Russia and additional European countries, parallel with the US clinical study, to accelerate the collection of robust data on the potential efficacy of opaganib against Covid-19, said Levitt.

The company is working with government agencies worldwide to allow more patients access to the investigational drug through clinical studies and compassionate use programs.

InnoCan InnoCan founders, from left, Ron Mayron, Iris Bincovich, Yoram Drucker. Photo by Rotem Lahav InnoCan Pharma Israel and Tel Aviv University tech-transfer company Ramot are collaborating to develop a new CBD-loaded exosome technology to fight lung inflammation.

Exosomes, small particles created from stem cells, can act as homing missiles targeting specific damaged organs and facilitating cell-to-cell communication.

Combining the cell-healing properties of exosomes with the anti-inflammatory properties of the cannabis-derived compound CBD is expected to have a strong synergetic effect. The treatment is administrated by inhalation.

Stero Biotechs Stero Biotechs of Bnei Brak has started a small clinical trial at Rabin Medical Center in Petah Tikva on the tolerability, safety, and efficacy of CBD-enhanced steroid treatment for hospitalized Covid-19 patients.

Steroid treatment is usually the first or second line of treatment for hospitalized patients. CBD enhances the therapeutic effect of steroid treatment and treats the bio-mechanism affected by the virus, the company explained.

Eybna and CannaSoul Two Israeli cannabis R & D firms, Eybna Technologies and CannaSoul Analytics, develop a proprietary terpene formulation for modulating cytokine storms.

Terpenes are organic compounds found in cannabis and other plants. Studies suggest they can be effective antiviral agents.

CannaSouls Cytokine Storm Assay (from its Myplant-Bio subsidiary) will aid in optimizing and customizing Eybnas novel NT-VRL inhaled formulation for treatment and prevention of viral infections in high-risk populations and actively ill patients.

The FDA considers this assay as a good predictor for cytokine storm response and immunotoxicity, and it is commonly required in the development of biological treatments, according to CannaSoul Chairman and CSO Prof. Dedi Meiri.

The NT-VRL formulation intended to be used via inhalation, said Eybna CEO Nadav Eyal. This delivery method dramatically increases the terpenes bioavailability by directly contacting the infected cells in the respiratory system.

CannaSoul aims to identify other cannabis molecules capable of suppressing a cytokine storm in response to Covid-19 without completely suppressing the immune system. It is also studying how cannabis molecules could modulate the ACE2 receptor, which allows the virus to inject its genetic expression into human cells.

Kamada Based in Rehovot, Kamada has begun supplying its experimental plasma-derived Hyperimmune IgG therapy for compassionate use in severe Covid-19 cases in Israel.

The treatment is based on plasma donated by recovered Israeli Covid-19 patients. One critically ill patient at Hadassah Medical Center showed initial improvement after having the experimental IgG therapy but ultimately did not survive.

During the third quarter of this year, Kamada expects to start a Phase 1/2 clinical study in hospitalized Covid-19 patients in Israel and hold a pre-IND meeting with the FDA to expand clinical development in the United States in partnership with Kedrion Biopharma.

Kedrion is collecting plasma from recovered American Covid-19 patients at 23 FDA-approved centers across the United States. This will be used by Kamada to manufacture additional batches of the product.

To the best of our knowledge, Kamada is the first company globally to complete manufacturing of a plasma-derived IgG product for the treatment of Covid-19, said Kamada CEO Amir London.

Israel Institute for Biological Research The government-run Israel Institute for Biological Research (IIBR) announced in May that analogs of two drugs for Gauchers disease proved effective against SARS-CoV-2.

This drug cocktail is made up of the FDA-approved Cerdelga and an analog of the second drug in advanced stages of the approval process.

The IIBR study on cell cultures demonstrated that the two-drug treatment significantly reduced the coronaviruss replication capacity and the destruction of the infected cell. This potential treatment is currently being tested in animals infected with the coronavirus.

The IIRB also isolated several critical coronavirus antibodies that successfully neutralized aggressive coronavirus in lab tests. These could form the basis of future treatment following further testing.

Pepticom Based in Jerusalem, Pepticom computationally designs novel peptide drug candidates using artificial intelligence. The company raised $5 million last year.

Three months ago, Pepticom began implementing its proprietary AI technology on various coronavirus proteins to identify novel peptides that inhibit the interaction between the spike protein of SARS-Cov-2 and the ACE2 receptor thereby stopping the virus from entering the cell.

CEO Immanuel Lerner says three such proteins have already been identified and are being validated in the lab.

Using AI is a fast way to find these peptides, which are less expensive and easier to produce than antibodies, Lerner tells ISRAEL21c. Many parties are interested in looking at our results and finding ways to develop this further.

Bonus BioGroup In April, Bonus BioGroup initiated a preclinical study of MesenCure, its unique drug for treating acute and life-threatening respiratory distress in coronavirus and pneumonia patients.

MesenCure consists of activated mesenchymal stromal (stem) cells from healthy adult donors. The activation of these MSCs is intended to boost their ability to reduce lung inflammation, promote regeneration of the diseased lung tissue, and alleviate respiratory and other symptoms in the lungs.

The development of MesenCure relies on more than a decade of related experience and technologies that Bonus BioGroup has used in developing its lead product, a tissue-engineered bone graft, also based on MSCs.

With the current coronavirus outbreak, Bonus BioGroup has started tissue culture studies into the potential of these MSCs, further activated, to alleviate inflammation, including in the lungs, and possibly attenuate the cytokine storm in COVID-19 patients, the company explained.

The preclinical study in several animal models is expected to be completed in the third quarter of 2020. The company said preliminary results indicate that following the treatment with MesenCure, the microscopic appearance of the treated lungs was similar to a healthy lung, and a significant improvement in additional related parameters was achieved.

Bonus BioGroup presented these results to 1,800 scientists, physicians, and public opinion leaders at the International Society for Cell & Gene Therapy virtual conference in May.

NanoGhost Technion-Israel Institute of Technology Prof. Marcelle Machluf developed a drug-delivery technology that uses reconstructed mesenchymal stem cells as nano-vesicles to transport medicine directly to a target.

NanoGhost is the startup she established to commercialize the technology, which has proven successful in treating pancreatic, lung, breast, prostate, and brain cancer in mice. The NanoGhost technology has been patented in the United States and Europe, with additional patents pending in India and China.

Now, Machluf is adapting her technology to create decoy NanoGhosts that attract and entrap the coronavirus, making for a less severe infection. She explains it in the video below.

Enlivex Enlivex Therapeutics of Ness Ziona is developing Allocetra, a novel immunotherapy medication to treat organ dysfunction and acute multiple organ failure associated with sepsis and Covid-19, as well as solid tumors.

Allocetra rebalances a severely unbalanced immune system by engaging with the immune systems own regulation mechanisms. It is designed to restore a safe immune balance following a cytokine storm.

Enlivex is starting to recruit Covid-19 patients in Israel and in the United States to test the potential effect of Allocetra on moderate to severe cases. A patent from the Japan Patent Office is expected during the third quarter of 2020.

Weizmann Institute of Science Organic chemist Nir London of the Weizmann Institute of Science in Rehovot is co-leading a collaborative project to identify small molecules that can bind to and inhibit a protease enzyme that the SARS-CoV-2 virus needs to reproduce.

London and his research team had previously developed an advanced method for identifying potential inhibitors for numerous proteins.

So far, we have made close to 800 compounds and tested more than 650 and keep getting closer to sufficiently potent inhibitors, London tells ISRAEL21c.

These inhibitors will be further investigated for their potential as a starting point for new drugs against the coronavirus.

London is working with researchers from Oxford University, Memorial Sloan Kettering Cancer Center, University of British Columbia, and Californian-based biotech company.

The Yucatan Times Newsroom

comments

Continued here:
13 promising Covid-19 treatments emerging from Israel - The Yucatan Times

Surat: Engineer falls to death from tenth floor of under construction Covid hospital – The Indian Express

By adminJuly 10, 2020Stem Cell Doctors

By: Express News Service | Surat | Published: July 10, 2020 8:50:59 pm He was immediately taken to the NCH trauma centre where doctors declared him dead on arrival.

A 56-year-old executive engineer fell down from the tenth floor of the Stem Cell Hospital at New Civil Hospital (NCH) in Surat, where work to convert the facility into a dedicated Covid hospital is in progress. It has not been established whether the engineer committed suicide or accidentally fell down, police said.

Jashwant Shihora (56), a resident of Parle Point area in Surat, who worked as an executive engineer at the electrical department of Project Implementation Unit, reached the Stem Cell Hospital at NCH on Friday morning, to conduct a routine check.

According to police sources, Jashwant had gone to the tenth floor alone and fell down under mysterious circumstances. The other labourers immediately gathered at the spot even as Jashwants head was profusely bleeding. He was immediately taken to the NCH trauma centre where doctors declared him dead on arrival.

Surat district collectorate officials along with Khatodara police had also reached the spot. The statements of a few engineers working there were taken and the police began a probe.

Khatodara police inspector KB Zala said, We have registered a case of accidental death and started a probe, It is difficult to say at this moment whether he had committed suicide or accidentally fallen down. He was alone at the topmost floor of the building. We are looking into all aspects.

In view of the rise in Covid-19 cases in Surat, Gujarat Chief Minister Vijay Rupani had arrived in the city on July 4 to take stock of the situation. While addressing media persons at the district collectors office, he had said, The Stem Cell Hospital building (600 beds) which at present is not being used, as some work is pending there, will be converted to a Covid hospital within a week. The Kidney Hospital building (700 beds) will also be converted into a dedicated Covid hospital.

Both buildings are located in the premises of the NCH campus and only their external structure has been made so far. Following the CMs announcement, district administrative officials had given contracts to three agencies to develop both hospitals.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Ahmedabad News, download Indian Express App.

The Indian Express (P) Ltd

Visit link:
Surat: Engineer falls to death from tenth floor of under construction Covid hospital - The Indian Express

Global Stem Cell Therapy Market Outlook 2025: Top Companies, Trends, Growth Factors Details by Regions, Types and Applications – Owned

By adminJuly 10, 2020Stem Cell Treatment

Now available with Market Study Report, LLC, this report on Stem Cell Therapy Market delivers a succinct analysis on industry size, regional growth and revenue forecasts for the upcoming years. The report further sheds light on significant challenges and latest growth strategies adopted by manufacturers who are a part of the competitive spectrum of this business domain.

Request a sample Report of Stem Cell Therapy Market at:https://www.marketstudyreport.com/request-a-sample/2422751?utm_source=primefeed.in&utm_medium=Ram

The recent document on the Stem Cell Therapy market includes a wide range assessment of this industry with thorough division of this vertical. As per the report, the Stem Cell Therapy market is determined to grow and increase the return over the estimated time period and will record an outstanding growth rate y-o-y over the predicted time period.

As per the report, the study provides critical estimations about the Stem Cell Therapy market related to the sales capacity, profit projections, market size, and several other important parameters. The Stem Cell Therapy market document also assesses details about the industry division along with the driving forces that impact the renumeration scale of this industry.

Important aspects of Stem Cell Therapy market with respect to the geographical landscape:

Ask for Discount on Stem Cell Therapy Market Report at:https://www.marketstudyreport.com/check-for-discount/2422751?utm_source=primefeed.in&utm_medium=Ram

An outline of important points of Stem Cell Therapy market report:

is explained in the study.

. The report includes data regarding these products and offers information about the market share of these products.

. It also speaks about the market share gained by the application segments.

The research report evaluates the Stem Cell Therapy market and claims that the industry is anticipated to register a significant revenue over the estimated time period. Data with regards to market dynamics such as challenges present in this vertical, growth opportunities, and the factors affecting the business domain.

For More Details On this Report: https://www.marketstudyreport.com/reports/global-stem-cell-therapy-market-2020-by-company-regions-type-and-application-forecast-to-2025

Related Reports:

1. Global Cabozantinib Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 Read More: https://www.marketstudyreport.com/reports/global-cabozantinib-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

2. Global Medicine for the Treatment of Advanced Thyroid Cancer Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 Read More: https://www.marketstudyreport.com/reports/global-medicine-for-the-treatment-of-advanced-thyroid-cancer-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Contact Us: Corporate Sales, Market Study Report LLC Phone: 1-302-273-0910 Toll Free: 1-866-764-2150 Email: [emailprotected]

Originally posted here:
Global Stem Cell Therapy Market Outlook 2025: Top Companies, Trends, Growth Factors Details by Regions, Types and Applications - Owned